Conduit Pharmaceuticals Faces Nasdaq Delisting
Ticker: CDTTW · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50, $1.00, $0.10 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, corporate-governance
TL;DR
Nasdaq's kicking Conduit Pharma off the exchange, vote coming up.
AI Summary
Conduit Pharmaceuticals Inc. reported on December 17, 2024, that it received a notice of delisting from the Nasdaq Stock Market due to failure to meet continued listing requirements. The company is also submitting matters to a vote of its security holders.
Why It Matters
This filing indicates a significant risk to investors as the company may be removed from a major stock exchange, potentially impacting liquidity and valuation.
Risk Assessment
Risk Level: high — Receiving a delisting notice from a major exchange like Nasdaq signifies severe financial distress or non-compliance, posing a substantial risk to shareholders.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange issuing delisting notice
- December 17, 2024 (date) — Date of earliest event reported
FAQ
What specific continued listing rule(s) did Conduit Pharmaceuticals Inc. fail to satisfy?
The filing states that Conduit Pharmaceuticals Inc. received a notice of delisting or failure to satisfy a continued listing rule or standard, but the specific rule(s) are not detailed in this 8-K summary.
What are the matters being submitted to a vote of security holders?
The filing indicates that matters are being submitted to a vote of security holders, but the specific proposals are not detailed in this 8-K summary.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is December 17, 2024.
What was Conduit Pharmaceuticals Inc.'s former company name?
Conduit Pharmaceuticals Inc.'s former company name was Murphy Canyon Acquisition Corp., with a date of name change on November 30, 2021.
What is the company's principal business address?
The company's principal business address is 4851 Tamiami Trail North, Suite 200, Naples, FL 34103.
Filing Stats: 1,341 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2024-12-20 17:00:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
- $1.00 — sted securities had closed at less than $1.00 per share over the previous 30 consecut
- $0.10 — s securities had a closing bid price of $0.10 or less for ten consecutive trading day
Filing Documents
- form8-k.htm (8-K) — 53KB
- 0001493152-24-051089.txt ( ) — 278KB
- cdt-20241217.xsd (EX-101.SCH) — 4KB
- cdt-20241217_def.xml (EX-101.DEF) — 29KB
- cdt-20241217_lab.xml (EX-101.LAB) — 36KB
- cdt-20241217_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On December 18, 2024, the Company convened the Annual Meeting. Proxies had been submitted by stockholders representing approximately 58.5% of the shares of the Company's common stock outstanding and entitled to vote, which constituted a quorum. At the Annual Meeting, the Company's stockholders voted on three proposals, each of which is described in more detail in the proxy statement. The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management's solicitation. Proposal 1 . Stockholders elected the six nominees for directors to serve until the Company's 2025 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified. The voting results were as follows: Director Name Votes For Votes Withheld Broker Non-Votes David Tapolczay 42,052,620 4,232,638 12,670,988 Freda Lewis-Hall 41,818,559 4,466,699 12,670,988 James Bligh 41,679,070 4,606,188 12,670,988 Faith L. Charles 41,372,614 4,912,644 12,670,988 Chele Chiavacci Farley 44,799,021 1,486,237 12,670,988 Andrew Regan 41,118,320 5,166,938 12,670,988 Proposal 2 . Stockholders ratified the selection of Marcum LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 54,309,718 4,355,671 290,856 0 Proposal 3 . Stockholders approved and adopted an amendment to the Company's Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of issued shares
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 20, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ David Tapolczay Name: David Tapolczay Title: Chief Executive Officer